Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of May 2023. The report documents the outcome of the Company's Annual General Meeting of Shareholders held on May 11, 2023, which followed a one-week adjournment from the original scheduled date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding shareholder voting results and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary event reported is the successful approval of all proposals presented to shareholders at the Annual General Meeting.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It confirms that all proposals were approved by the requisite majority in accordance with the Israeli Companies Law and the Company's articles of association, referencing a Proxy Statement filed on March 30, 2023, for further details.
Key Facts for Investor Verification
- All shareholder proposals at the May 11, 2023, Annual General Meeting were approved.
- The meeting was held following a one-week adjournment from the original date.
- Details of the proposals are contained in the Proxy Statement filed as Exhibit 99.2 to a Form 6-K dated March 30, 2023.
- This filing incorporates information by reference into the Company's registration statements on Form F-3 and Form S-8.